What is NDC 82511-001?

82511-001 is the product NDC for Capecitabine, Capecitabine 150 mg/1 tablet, film coated, listed with the FDA by Teyro Labs Private Limited. It has 1 package NDC, shown above in 10- and 11-digit form.

Teyro Labs Private Limited, NDC labeler code 82511. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Capecitabine?

30 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Capecitabine NDC 82511-001 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)82511-001Labeler and product segments. Claims need a package NDC.

Product NDC at billing width82511-0001Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
82511-001-15	8251100011582511000115	60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (82511-001-15)Marketed from Sep 1, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Capecitabine
Generic name (nonproprietary): capecitabine
Active ingredients: Capecitabine — 150 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Teyro Labs Private LimitedNDC labeler code 82511
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 217237
Marketing start: Feb 16, 2022
Listing expires: Dec 31, 2026
Other FDA classes: Nucleic Acid Synthesis Inhibitors (Mechanism)
Identifiers: Product ID 82511-001_2b3f98b5-d81c-d87d-e063-6294a90a7e87SPL ID 2b3f98b5-d81c-d87d-e063-6294a90a7e87SPL set ID 0c873e5b-51c2-4685-86c5-53f98563b093RxCUI 200327, 200328UNII 6804DJ8Z9U
Pharmacologic class: Nucleoside Metabolic Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N482511000115 followed by a unit qualifier and the quantity

Package 82511-0001-15. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 8, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Capecitabine tablets is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. ( 1.1 ) treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) Breast Cancer treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated. ( 1.2 ) treatment of patients…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 82511-001

What is NDC 82511-001?: 82511-001 is the product NDC for Capecitabine, Capecitabine 150 mg/1 tablet, film coated, listed with the FDA by Teyro Labs Private Limited. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Capecitabine.
What is the active ingredient?: Capecitabine.
Who is the labeler?: Teyro Labs Private Limited, NDC labeler code 82511. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Capecitabine?: 30 other product NDCs are listed under this name. See all Capecitabine NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Capecitabine NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Capecitabine	Capecitabine 150 mg/1	Tablet, Film coatedOral	CivicaScript LLC	82249-207	82249-0207-60
Capecitabine	Capecitabine 500 mg/1	Tablet, Film coatedOral	CivicaScript LLC	82249-210	82249-0210-12
Capecitabine	Capecitabine 500 mg/1	Tablet, Film coatedOral	BluePoint Laboratories	68001-644	68001-0644-07
Capecitabine	Capecitabine 150 mg/1	Tablet, Film coatedOral	BluePoint Laboratories	68001-643	68001-0643-06
capecitabine	Capecitabine 500 mg/1	Tablet, Film coatedOral	NorthStar RxLLC	72603-303	72603-0303-01
capecitabine	Capecitabine 150 mg/1	Tablet, Film coatedOral	Camber Pharmaceuticals, Inc.	31722-774	31722-0774-60
capecitabine	Capecitabine 500 mg/1	Tablet, Film coatedOral	Camber Pharmaceuticals, Inc.	31722-775	31722-0775-1231722-0775-60
Capecitabine	Capecitabine 500 mg/1	TabletOral	Quallent Pharmaceuticals Health LLC	82009-112	82009-0112-12
Capecitabine	Capecitabine 500 mg/1	Tablet, Film coatedOral	Cipla USA Inc.	69097-948	69097-0948-08
Capecitabine	Capecitabine 150 mg/1	Tablet, Film coatedOral	Cipla USA Inc.	69097-949	69097-0949-03

All 31 Capecitabine NDCs

Other NDCs under ANDA 217237

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 217237
Product	Strength	Form · route	Labeler	Product NDC
Capecitabine	Capecitabine 500 mg/1	Tablet, Film coatedOral	Teyro Labs Private Limited	82511-002